PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology... Show more
PolyPid Ltd. (PYPD) is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel. The company develops locally administered, long-acting, controlled-release therapeutics built on a proprietary drug-delivery platform, with a primary focus on improving surgical outcomes. Its most advanced program, D-PLEX100, targets the prevention of surgical site infections, a significant source of post-operative complications, extended hospital stays, and rising healthcare costs. Investors follow PolyPid because of the late-stage status of its lead candidate, its validated delivery technology, and its path toward potential commercialization.
PolyPid was incorporated under the laws of Israel in 2008 and began operations on February 28, 2008. The company listed on the Nasdaq Global Market through an initial public offering (IPO) in June 2020. It is led by Chief Executive Officer Dikla Czaczkes Akselbrad, who previously served as the company's chief financial officer. As a small-cap development-stage enterprise, PolyPid employs roughly 60 to 75 people and maintains subsidiaries in the United States and Romania.
At the center of the company's business model is its proprietary PLEX technology, which the company has branded Kynatrix. The platform pairs active pharmaceutical ingredients (APIs) with a polymer-lipid encapsulation matrix, enabling the precise, localized delivery of drugs at controlled release rates over periods ranging from several days to months. By delivering therapy directly at the treatment site, the technology aims to achieve high local drug concentrations while limiting systemic exposure.
PolyPid's lead candidate, D-PLEX100, uses Kynatrix to deliver the broad-spectrum antibiotic doxycycline directly into the surgical site. The goal is to provide prolonged, continuous antibacterial activity for approximately 30 days to prevent surgical site infections (SSIs) following abdominal colorectal surgery with large incisions. In its pivotal Phase 3 SHIELD II trial, D-PLEX100 met its primary efficacy endpoint and demonstrated a clinically meaningful reduction in SSI incidence versus standard of care. The U.S. Food and Drug Administration (FDA) has granted D-PLEX100 Breakthrough Therapy Designation, and the company's New Drug Application (NDA) — a formal request for marketing approval — has been accepted for review under priority status.
Beyond D-PLEX100, PolyPid is advancing an early-stage pipeline that applies its delivery platform to other therapeutic areas. These include oncology programs such as OncoPLEX for the treatment of solid tumors, as well as research in metabolic diseases such as obesity and diabetes. The company has also disclosed early-stage work on a long-acting GLP-1 program and on a Kynatrix-based candidate for diabetic foot infections. This broader pipeline illustrates how PolyPid intends to leverage a single core technology across multiple markets, though these programs remain at preclinical or early development stages.
PolyPid's financial profile reflects a typical pre-revenue biotech: the company has historically been funded through equity offerings, research grants, and, more recently, partnership economics. In 2026, PolyPid announced an exclusive agreement with Azurity Pharmaceuticals to commercialize D-PLEX100 in the United States and Canada, with PolyPid retaining manufacturing and supply responsibilities as well as global commercial rights outside those regions. The agreement includes upfront and milestone payments plus tiered royalties, providing a framework for the company's transition toward commercial-stage operations.
Investor attention on PYPD centers on several long-term factors. First, D-PLEX100 addresses a substantial unmet need: surgical site infections are common, costly complications for which there are limited localized, long-acting prevention options. Second, the positive Phase 3 results provide clinical validation for both the lead candidate and the underlying Kynatrix platform, supporting potential expansion into additional surgical and therapeutic indications. Third, the Azurity partnership reduces some commercial execution risk in the company's largest market while providing non-dilutive funding and milestone economics. Finally, the platform's versatility in areas such as oncology and metabolic disease offers a long-term growth narrative beyond a single product.
Investors should weigh several significant risks before considering PYPD. As a clinical-stage company, PolyPid has no approved commercial products and has reported recurring net losses and an accumulated deficit. Its financial statements have included disclosures raising substantial doubt about its ability to continue as a going concern, underscoring its dependence on additional financing and partnership milestones. The company's near-term value is heavily concentrated in a single lead candidate; any regulatory setback, delay, or negative clinical outcome for D-PLEX100 could have a material impact. Broader risks include intense competition in the biopharmaceutical industry, reliance on a commercial partner for U.S. launch execution, manufacturing scale-up challenges, and the inherent uncertainty of the FDA review process. As with many development-stage biotechnology companies, the shares can be highly volatile and carry a distinct risk profile.
Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. Whether you are researching clinical-stage biotechs like PolyPid or broader market themes, the AI Screener offers a structured way to narrow your focus and refine your watchlist.
PolyPid (PYPD) is a development-stage Israeli biopharmaceutical company built around a proprietary long-acting, locally administered drug-delivery platform. Its lead candidate, D-PLEX100, targets a meaningful unmet need in surgical site infection prevention and has advanced through positive late-stage clinical data into regulatory review, supported by a U.S. commercialization partnership. While the company's pipeline and platform offer a broad long-term opportunity set, its pre-revenue financial profile and dependence on regulatory and financing outcomes make it a high-risk, high-uncertainty investment that merits careful, independent due diligence.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes
Industry Biotechnology